01 - Nuove opzioni terapeutiche per la pratica clinica nel GI

from "We're on the ball" - Nuovi farmaci e nuove indicazioni · host ACCMED

A Cura di Alessandro Pastorino Parliamo delle nuove rimborsabilità AIFA per pembrolizumab nel colon-retto MSI, nivolumab nell'esofago squamoso e trifluridina-tipiracil nell'adenocarcinoma gastrico. Importante anche l'uso nominale di durvalumab in prima linea nelle vie biliari.

Episode metadata supplied by the publisher feed · Published Apr 4, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

01 - Nuove opzioni terapeutiche per la pratica clinica nel GI

0:00 5:06

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of "We're on the ball" - Nuovi farmaci e nuove indicazioni?

This episode is 5 minutes long.

When was this "We're on the ball" - Nuovi farmaci e nuove indicazioni episode published?

This episode was published on April 4, 2022.

Can I download this "We're on the ball" - Nuovi farmaci e nuove indicazioni episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!